Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies

Inclusion Criteria:

• Aged 18 years or older, with lymphoid malignancies of B-cell origin as follows:

*Indolent / aggressive B-cell (NHL) Non- Hodgkin's Lymphoma:

EXCLUDING: Burkitt lymphoma and precursor B-lymphoblastic leukemia/lymphoma

INCLUDING: any non-Hodgkin's B-cell malignancy such as CLL and rare non-Hodgkin's B-cell
subtypes such as Hairy Cell Leukemia, Waldenstrom macroglobulinemia, Mantle cell lymphoma,
transformed NHL histologies, etc.

*Hodgkin's lymphoma

- Life expectancy of 12 weeks or longer.

- Subject must have received ≥ 1 prior treatment regimen.

- The subject must not be a candidate for potentially curative therapy, including stem
cell transplant.

Exclusion Criteria:

- Received an investigational study drug within 28 days or 5 half-lives (whichever is
longer) prior to receiving the first dose of study drug.

- Received any approved anticancer medications within 21 days or 5 half-lives (whichever
is longer) prior to receiving their first dose of study drug (42 days for
nitrosoureas) EXCEPT steroids at ≤ 10 mg prednisone daily (or equivalent).

- Has any unresolved toxicity ≥ Grade 2 from previous anticancer therapy.

- Has history of brain metastases or spinal cord compression, or lymphoma involving the
central nervous system.

- Has an Eastern Cooperative Oncology Group (ECOG) performance status of ≥ 3.

- Received allogeneic hematopoietic stem cell transplant within the last 6 months, or
has active graft versus host disease (GVHD) following allogeneic transplant, or is
currently receiving immunosuppressive therapy following allogeneic transplant.

- Received autologous hematopoietic stem cell transplant within the last 3 months.

- Laboratory parameters not within the protocol-defined range.

- Current or recent history (<30 days prior to screening and/or <45 days prior to
dosing) of a clinically meaningful bacterial, fungal, parasitic or mycobacterial
infection.

- Current clinically active viral infection.

- Known history of infection with the human immunodeficiency virus (HIV).

- History of active hepatitis or positive serology for hepatitis.